BURLINGAME, Calif., Oct. 03, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. CRVS, a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that it will present data from its Phase 1/1b clinical trial of CPI-006 at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting 2019 in National Harbor, Maryland, taking place November 6-10.
Corvus will present data on CPI-006 in an oral presentation and two poster sessions:
| Oral Presentation: | |
| Abstract O40: | Immunobiology and clinical activity of CPI-006, an anti-CD73 antibody with immunomodulating properties in a phase 1/1b trial in advanced cancers. |
| Presenter: | Jason J. Luke, M.D., FACP, Director of the Cancer Immunotherapeutics Center, Associate Professor of Medicine, the University of Pittsburgh Medical Center and Hillman Cancer Center |
| Session Title: | Session 204: Immune Checkpoints: Newer Targets and Update on Combinations |
| Date and Time: | Friday, November 8, 2019 from 3:45 pm – 4:00 pm ET |
| Poster Presentations: | |
| Poster P125: | Adenosine and AMP gene expression profiles predict response to adenosine pathway therapies and indicate a need for dual blockade of CD73 and A2AR with CD73 inhibitors. |
| Presenter: | Stephen Willingham, PhD, Corvus Senior Scientist |
| Poster Session: | Biomarkers, Immune Monitoring, and Novel Technologies |
| Date and Time: | Friday, November 8, 2019 from 7:00 am – 8:00 pm ET |
| Location: | Poster Hall: Prince George AB / Gaylord National Hotel & Convention Center |
| Poster P434: | A phase 1/1b study to evaluate the humanized anti-CD73 antibody, CPI-006, as a single agent, in combination with CPI-444, and in combination with pembrolizumab in adult patients with advanced cancers. |
| Presenter: | Mehrdad Mobasher, M.D., Corvus Vice President and Chief Medical Officer |
| Poster Session: | Clinical Trial in Progress |
| Date and Time: | Saturday, November 9, 2019 from 7:00 am – 8:30 pm ET |
| Location: | Poster Hall: Prince George AB / Gaylord National Hotel & Convention Center |
About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies. Corvus' lead product candidates are ciforadenant (CPI-444), a small molecule inhibitor of the A2A receptor, and CPI-006, a humanized monoclonal antibody directed against CD73 that exhibits immunomodulatory activity and blockade of adenosine production. These candidates are being studied in ongoing Phase 1 and 2 clinical trials in patients with a wide range of advanced solid tumors. Ciforadenant is being evaluated in a successive expansion cohort trial examining its activity both as a single agent and in combination with an anti-PD-L1 antibody. CPI-006 is being evaluated in a multicenter Phase 1/1b clinical trial as a single agent, in combination with ciforadenant, and with pembrolizumab. The Company's third clinical program, CPI-818, an oral, small molecule drug that has been shown to selectively inhibit ITK, is in a multicenter Phase 1/1b clinical trial in patients with several types of T-cell lymphomas. For more information, visit www.corvuspharma.com.
INVESTOR CONTACT:
Leiv Lea
Chief Financial Officer
Corvus Pharmaceuticals, Inc.
650-900-4522
LLea@corvuspharma.com
MEDIA CONTACT:
Sheryl Seapy
W2O pure
+1 213-262-9390
sseapy@purecommunications.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
